Tech Company Financing Transactions
Cinclus Pharma Funding Round
Claret Capital Partners participated in a $32 million capital raise for Cinclus Pharma. The round was announced on 3/13/2026.
Transaction Overview
Company Name
Announced On
3/13/2026
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Undisclosed
Investors
Claret Capital Partners (Johan Kampe)
Proceeds Purpose
This funding enables us to move with higher speed through the final stage of our clinical program, with the goal of achieving market approval in both the US and Europe. Our first Phase III study, HEEALING 1, remains on track and was fully financed prior to this agreement, with topline results expected in the second half of 2026. This new capital allows us to look beyond that milestone and focus entirely on the fastest possible route to the patients who need this next-generation treatment.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Kungsbron 1
Stockholm, 111 22
Sweden
Stockholm, 111 22
Sweden
Phone
Website
Email Address
Overview
Vision: An improved quality of life for people worldwide living with gastric acid related diseases. Mission: To introduce game changing products impacting standard of care for patients with gastric acid related diseases, underpinned by the superior P-CAB linaprazan glurate.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christer Ahlberg
Browse more venture capital transactions:
Prev: 3/13/2026: Tower Computing venture capital transaction
Next: 3/13/2026: AgZen venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to document tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs